Global Assisted Reproductive Technology Market Outlook 2025–2030: Trends, Opportunities, and Regional Insights

The global Assisted Reproductive Technology (ART) market was valued at USD 25.71 billion in 2024 and is projected to reach USD 27.71 billion by 2025, expanding to USD 40.34 billion by 2030 at a CAGR of 7.8%. Growth is fueled by rising infertility prevalence, delayed parenthood, lifestyle changes, and increasing social acceptance of fertility treatments. Innovations in in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), cryopreservation, and digital tools such as AI-driven embryo selection are transforming ART into a precision-based, patient-centric healthcare segment. Expanding public funding, insurance coverage, and global awareness around fertility management are further driving adoption. Key challenges include high treatment costs, regulatory complexities, and disparities in access. The market is segmented by product, technology, indication, procedure type, end user, and geography. North America and Europe exhibit mature, insurance-driven demand, while Asia-Pacific and emerging markets demonstrate strong growth potential. Leading companies, including Merck KGaA, Ferring, Cooper Surgical, Vitrolife, and FUJIFILM Irvine Scientific, are investing in technological innovation, M&A, and integrated fertility ecosystems to maintain competitive advantage. This report offers a comprehensive outlook for stakeholders, investors, and healthcare providers seeking to capitalize on opportunities in the evolving ART market.